Opioid use disorder treatment inaccessible for many Appalachian patients, study finds

Scientists from the Atlanta-based Emory Rollins School of Public Health discovered that about a quarter of pharmacies in rural Kentucky denied buprenorphine to patients with prescriptions, regardless of several federal and state efforts to increase access to the drug, which deals with opioid usage condition. The scientists likewise noted that buprenorphine minimizes the risk of overdose, in addition to HIV and liver disease C infection.

Katie Adams –
Friday, August 21st, 2020
Print|Email.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by clicking here.

More short articles on opioids:49 states submit $2.15 trillion opioid epidemic suit against Purdue PharmaPregnant ladies face challenges in obtaining opioid usage condition treatment, study finds80% of Americans cant accurately identify opioids, study finds.

Clients in main Appalachia, the epicenter of the opioid epidemic, face barriers in accessing treatments for opioid usage condition, according to a research study published Aug. 20 in the New England Journal of Medicine.

They composed that the factors for these denials might come from an absence of physician-pharmacist trust, preconception versus patients with opioid usage disorder and drug makers contradictory technique of keeping track of opioid sales, in which they group together both opioids and the drugs that treat opioid usage disorder..